Compare Oklo Inc (OKLO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Sana Biotechnology Inc — how do they compare? Oklo Inc trades at $34.7 (market cap $6.43B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Oklo Inc is far larger — about 7.7× Sana Biotechnology Inc's market cap, and Oklo Inc is more actively traded (16,238,368 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 32 Days and Sana Biotechnology Inc for 23 Days on average.
| OKLO | SANA | |
|---|---|---|
Market Cap | $6.43B | $836.71M |
Volume | 16,238,368 | 4,507,444 |
Sector | Utilities | Health |
52-Week High | $174.14 | $5.92 |
52-Week Low | $34.57 | $2.68 |
Typical Hold Time | 32 Days | 23 Days |
Enterprise Value | $3.97B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.57, down 6.11% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strong with 71% buy ratings and a $78.63 price target. Recent news highlights nuclear industry momentum but questions OKLO's commercialization timeline versus established peers.
Outlook hinges on project execution amid substantial cash burn. High institutional financing supports growth but dilution risks persist. The stock offers speculative upside if nuclear contracts materialize, but faces near-term execution and competitive challenges in the small modular reactor market.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
